Clinical Trials in New York

Showing 8041-8060 of 17,259 trials

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

NCT03262103

The purpose of this study is to test an approach of stimulating the body's immune system to attack prostate cancer. This study will test injection of a substance polylysine and carboxymethylcellulose (Poly-ICLC, Hiltonol®)through a needle guided by MRI (magnetic resonance imaging) ultrasound fusion technology into the prostate gland. Poly ICLC has been used to help the body in its fight against cancer. The first aim of the study is to determine the highest dose of a substance Poly-ICLC (Hiltonol®) that can be safely tolerated by the study participants. The second aim of the study is to find out the toxicity or side effects of poly-ICLC.

Prostate Cancer

Ashutosh Kumar Tewari13 participantsStarted Jun 2017

New York, New York, United States

COMPLETEDPhase 2< 1 mile

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

NCT03486899

This is a study of experimental medication BMS-986036 given to adults with Nonalcoholic Steatohepatitis (NASH; the buildup of fat and inflammation in the liver that is not caused by alcohol) and stage 3 liver fibrosis (severe fibrosis).

Liver FibrosisNonalcoholic Fatty Liver Disease (NAFLD)Nonalcoholic Steatohepatitis

Bristol-Myers Squibb197 participantsStarted Jun 2018

Madison, Alabama, United States • Chandler, Arizona, United States • Phoenix, Arizona, United States +86 more locations

Neoadjuvant Hiltonol® (PolyICLC) for Prostate Cancer

A Study of Experimental Medication BMS-986036 in Adults With Nonalcoholic Steatohepatitis (NASH) and Stage 3 Liver Fibrosis

Find Trials by Condition in New York

Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma

Safety, Tolerability, and Efficacy of AXA1125 in NASH With Fibrosis

A Study of LY2140023 in Schizophrenia Patients With Prominent Negative Symptoms

The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis

A Comparison Study of LY2140023 and Aripiprazole in Schizophrenia Patients

Lovastatin for the Treatment of Mildly Active Rheumatoid Arthritis

Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma That Can Be Removed by Surgery

An Exploratory, Open-Label, Oligo-Center Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Intravenous DNV3837 in Subjects With Clostridium Difficile Infection

CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients

Study to Evaluate the Safety and Efficacy of SDP-4 in Subjects With Dry Eye Disease (DED)

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Feasibility Study for GORE® TAG® Thoracic Branch Endoprosthesis to Treat Proximal Descending Thoracic Aortic Aneurysms

A Treatment Use Protocol for Subjects Continuing on From the Open-label Extension 0601

Platelet Rich Plasma (PRP) in Total Knee Replacement

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to Rituximab

Phase 1 Study to Assess the Safety, PK and PD of INBRX-101 in Adults With Alpha-1 Antitrypsin Deficiency

A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours